ClinicalTrials.gg
CompletedNCT00790127Updated May 20, 2011

Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia

A Phase 1/2 interventional study of HQK-1001 and Placebo in Beta Thalassemia, sponsored by HemaQuest Pharmaceuticals Inc.. Completed at 2 sites in 2 countries. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2011-05-20.

Sponsored by HemaQuest Pharmaceuticals Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
12 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies in beta-Thalassemia with a site in Lebanon — 2 open to participants now, 4 under way, 3 of them phase 3. beta-Thalassemia · Lebanon.

Enrollment
17th of 20
21 · median 69
Started
2009
the only one that year
Phase 1/2
Only one
of the 21
Registered
3rd of 21
by date
Lead sponsor
1 of 21
HemaQuest Pharmaceuticals Inc.

Among the 21 studies in beta-Thalassemia with a site in Lebanon, this one is the 17th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2009, is the only one in phase 1/2, and was the 3rd registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

2 of the 21 studies in beta-Thalassemia with a site in Lebanon are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Lebanon have not opened yet or have stopped. Only those recruiting at a site in Lebanon →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in beta-Thalassemia with a site in Lebanon, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of HQK-1001 administered daily for 8 weeks in subjects with beta thalassemia intermedia

03

Conditions studied

  • Beta Thalassemia

Browse trials for

04

Who can participate

Ages eligible
12 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of beta thalassemia intermedia or E beta thalassemia
  • Average of the initial two hemoglobin levels of less than 10 g/dL within ≥ 30 days prior to randomization.
  • Age ≥ 12 and ≤ 60 years
  • Able and willing to give or assent (if less than 18 years of age) and comply with all study procedures
  • If female and of , must have a documented negative pregnancy test at Day -1 and must agree to use one or more locally medically accepted methods of in the month prior to randomization, through the entire study, and for 4 weeks after the last dosing of study medication

Exclusion criteria

Exclusion Criteria:

  • Spleen palpable ≥ 2 cm below the left costal margin
  • Pulmonary hypertension requiring oxygen therapy
  • > 450 msec on screening
  • Infection with , requiring therapy
  • Known infection with
  • Red blood cell (RBC) transfusions within 2 months prior to administration of study medication with stable levels
  • Fever greater than 38.5°C in the week prior to administration of study medication
  • > 4x (ULN)
  • Baseline elevation of CPK value prior to randomization
  • Treatment with hydroxyurea within 2 months prior to administration of study medication
  • Cancer diagnosis within 5 years of randomization (except for non-melanoma cutaneous )
  • Serum creatinine > 1.5 mg/dl
  • Received systemic therapy within 30 days prior to randomization
  • Currently pregnant or breast feeding a child
  • Subject history of arrhythmias or syncope
  • Known current drug or alcohol abuse
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    HQK-1001

    HQK-1001

    Drug: HQK-1001

Interventions

  • DrugDimebutic acidStudies of Dimebutic acidDimebutic acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days

  • DrugPlacebo

    Matching placebo capsules administered once a day, orally, for 56 days

06

What researchers measure

Primary outcomes

  1. Safety as assessed by (1) adverse events, (2) laboratory values (3) vital signs (4) physical exam

    Time frame: 168 days

Secondary outcomes

  1. Pharmacokinetics assessed by plasma drug concentration levels

    Time frame: 140 days

  2. Pharmacodynamics assessed by red blood cell production and induction of fetal hemoglobin

    Time frame: 168 days

07

Study locations

2 sites
  • Chronic Care Center
    Beirut, Lebanon
  • Siriraj Hospital
    Bangkok, Bangkoknoin District 10700, Thailand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2008
First posted
Nov 13, 2008
Start
Mar 2009
Primary completionActual
May 2010
CompletionActual
May 2010
Results delay requested
May 13, 2011
Last update
May 20, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00790127
Lead sponsor
HemaQuest Pharmaceuticals Inc.
First posted
Nov 13, 2008
Start date
Mar 2009
Primary completion
May 2010
Completion
May 2010
Last update
May 20, 2011

Study contacts

Noppadol Siritanaratkul, MD
principal investigator · Siriraj Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimebutic acid

Start the discussion